Rubidium Rb 82

Revision as of 15:19, 22 April 2015 by Rabin Bista (talk | contribs)
Jump to navigation Jump to search

Rubidium Rb 82
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING: UNINTENDED STRONTIUM-82 (SR-82) AND STRONTIUM-85 (SR-85) RADIATION EXPOSURE:
See full prescribing information for complete Boxed Warning.
UNINTENDED STRONTIUM-82 (SR-82) AND STRONTIUM-85 (SR-85) RADIATION EXPOSURE:
  • Unintended radiation exposure occurs when the levels of Sr-82 or Sr-85 in the rubidium Rb 82 chloride injection exceed specified limits [see Warnings and Precautions (5.1)]

Perform generator eluate tests:

Record each generator eluate volume, including waste and test volumes, and keep a record of the cumulative eluate volume [see Dosage and Administration (2.4)]. Determine Rb-82, Sr-82, Sr-85 in the generator eluate: ●Once a day, prior to any drug administrations, and ●At additional daily tests after detection of an Alert Limit. Alert Limits are: ○14 L for the generator’s cumulative eluate volume, or ○An eluate Sr-82 level of 0.002 μCi/ mCi Rb-82, or ○An eluate Sr-85 level of 0.02 Sr-85 μCi/ mCi Rb-82. ○Perform the additional daily tests at time points determined by the day’s elution volume; tests are performed every 750 mL [see Dosage and Administration (2.5)]. Stop use of a generator at an Expiration Limit of: ○17 L for the generator’s cumulative eluate volume, or ○42 days post generator calibration date, or ○An eluate Sr-82 level of 0.01 μCi /mCi Rb-82, or

○An eluate Sr-85 level of 0.1 μCi /mCi Rb-82

Overview

Rubidium Rb 82 is a Diagnostic Agent that is FDA approved for the diagnosis of coronary artery disease. There is a Black Box Warning for this drug as shown here. Common adverse reactions include Unintended radiation exposure.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

CardioGen-82 is a closed system used to produce rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

Dosage

Infusion System Use CardioGen-82 only with an infusion system specifically designed for use with the generator and capable of accurate measurement and delivery of doses of rubidium Rb 82 chloride injection. Follow instructions in the Infusion System User’s Guide for the set up and intravenous infusion of rubidium Rb 82 chloride injection dose(s).

2.2 Rubidium Rb 82 Chloride Injection Dosage The recommended adult single dose of rubidium Rb 82 chloride injection is 1480 MBq (40 mCi) with a range of 1110-2220 MBq (30-60 mCi).

Do not exceed a single dose of 2220 MBq (60 mCi). Use the lowest dose necessary to obtain adequate cardiac visualization consistent with the dosing goal of as low as reasonably achievable (ALARA). Individualize the dose by considering factors such as body size, and the imaging equipment and technique. Administer the single dose at 50 mL/minute through a catheter inserted into a large peripheral vein; do not to exceed a total infusion volume of 100 mL. Administer two separate single doses to complete rest and stress myocardial perfusion imaging as follows:


Administer a single (“rest”) rubidium Rb-82 chloride dose; Start imaging 60-90 seconds after completion of the infusion of the rest dose and acquire images for 5 minutes; if a longer circulation time is anticipated (e.g., in a patient with severe left ventricular dysfunction), start imaging 120 seconds after the rest dose. For stress imaging:

Begin the study 10 minutes after completion of the resting dose infusion, to allow for sufficient Rb-82 decay; Administer a pharmacologic stress agent in accordance with its prescribing information; After an interval of 3 minutes, infuse a single (“stress”) rubidium Rb-82 chloride dose; Start imaging 60-90 seconds after completion of the stress Rb-82 chloride dose infusion and acquire images for 5 minutes; if a longer circulation time is anticipated start imaging 120 sec after the stress dose. 2.3 Drug Handling Limit the use of radiopharmaceuticals to physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides. Wear waterproof gloves and effective shielding when handling rubidium Rb-82 chloride injection and the infusion system. Observe aseptic techniques in all drug handling. Use only additive-free Sodium Chloride Injection USP to elute the generator. Visually inspect the drug for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer eluate from the generator if there is any evidence of foreign matter. 2.4 Directions for Eluting Rubidium Rb 82 Chloride Injection Allow at least 10 minutes between elutions for regeneration of Rb-82. Elute with additive-free Sodium Chloride Injection USP only. Additives (particularly calcium ions, to which strontium ions are chemically analogous), may cause the release of substantial amounts of Sr-82 and/or Sr-85 into the eluate regardless of the age or prior use of the generator. Discard the first 50 mL eluate each day the generator is first eluted. Employ proper safety precautions since the eluate contains radioactivity. Maintain an on-going record of all eluate volumes (washing, testing, dosing volumes), including a summary of the cumulative volume of eluate from the generator. 2.5 Eluate Testing Protocol Use additive-free sodium chloride injection USP for all elutions. Apply aseptic technique throughout.

Before administering rubidium Rb 82 chloride injection to the first patient each day, perform the following test:

Strontium Alert Limits and Mandatory Eluate Testing:

Use an ionization chamber-type dose calibrator for eluate testing. Daily, before administering rubidium Rb 82 chloride injection to any patient, perform an eluate testing to determine Rb-82, Sr-82, and Sr-85 levels Perform additional daily eluate tests after detecting any of the following Alert Limits: 14 L total elution volume has passed through the generator column, or Sr-82 level reaches 0.002 µCi per mCi Rb-82, or Sr-85 level reaches 0.02 µCi per mCi Rb-82. Perform the additional daily eluate tests at time points determined by the day’s elution volume; tests are performed every 750 mL.

For example, if an Alert Limit were reached and the clinical site eluted less than 750 mL from the generator during the day, then no additional eluate tests would have been performed that day. If the same clinical site the next day eluted 1,500 mL from the generator, then the site would have performed three tests that day: 1) the required daily test that precedes any patient dosing, 2) a test at the 750 mL elution point, and 3) a test at the 1,500 mL elution point. If a generator’s Alert Limit is reached, the clinical site performs the additional daily tests (at intervals of 750 mL) each subsequent day the generator is used. The additional tests are necessary to promptly detect excessive Sr-82 and/or Sr-85 in eluates. Rubidium Eluate Level Testing:

Set a dose calibrator for Rb-82 as recommended by the manufacturer or use the Co-60 setting and divide the reading obtained by 0.548. Obtain the reading from the instrument in millicuries. Elute the generator with 50 mL of Sodium Chloride Injection USP and discard the eluate (first elution). Allow at least 10 minutes for the regeneration of Rb-82, then elute the generator with 50 mL of Sodium Chloride Injection USP at a rate of 50 mL/min and collect the eluate in a stoppered glass vial (plastic containers are not suitable). Note the exact time of end of elution (E.O.E.). Using the dose calibrator, determine the activity of Rb-82 and note the time of the reading. Correct the reading for decay to the E.O.E. using the appropriate decay factor for Rb-82 (see Table 1). Note: If the reading is taken 2 1/2 minutes after end of elution, multiply the dose calibrator reading by 4 to correct for decay. Strontium Eluate Level Testing: Using the sample obtained for the Rb-82 activity determination, allow the sample to stand for at least one hour to allow for the complete decay of Rb-82. Measure the activity of the sample in a dose calibrator at the setting recommended by the manufacturer for Rb-82 and/or Sr-82. As an alternative, use the Co-60 setting and the reading obtained divided by 0.548. Set the instrument to read in microcuries and record the reading in the display. Calculate the ratio (R) of Sr-85/Sr-82 on the day (post-calibration) of the measurement using the ratio of Sr-85/Sr-82 on the day of calibration provided on the generator label and the Sr-85/Sr-82 Ratio Factor from Table 2. Determine R using the following equation: R = [Sr-85] / [Sr-82] on calibration date X Ratio Factor on the day (post-calibration) of measurement Use a correction factor (F) of 0.478 to compensate for the contribution of Sr-85 to the reading. Calculate the amount of Sr-82 in the sample using the following equation: Sr-82 (μCi) = dose calibration reading (μCi) / [1 + (R) (F)]Example: dose calibrator reading (μCi) = 0.8; Sr85/Sr82 ratio (R) =1.48; correction factor (F) = 0.478.Sr-82 (μCi) = 0.8 / [1 + (1.48)(0.478)] = 0.47

Determine if Sr-82 in the eluate exceeds an Alert or Expiration Limit by dividing the μCi of Sr-82 by the mCi of Rb-82 at End of Elution (see below for further instructions based on the Sr-82 level) Example: 0.47 μCi of Sr-82; 50 mCi of Rb-82 E.O.E. 0.47 μCi Sr-82 / 50 mCi Rb-82 = 0.0094 μCi/mCi Rb-82 (is above Alert Limit of 0.002; additional daily eluate testing must be performed)

Determine if Sr-85 in the eluate exceeds an Alert or Expiration Limit by multiplying the result obtained in step 10 by (R) as calculated in step 7 (above). Example: 0.0094 x 1.48 = 0.014 μCi Sr-85/mCi Rb-82 (test result is below Alert and Expiration Limits)

2.6 CardioGen-82 Expiration Stop use of the CardioGen-82 generator once any one of the following Expiration Limits is reached.

A total elution volume of 17 L has passed through the generator column, or 42 days post calibration date, or An eluate Sr-82 level of 0.01 μCi /mCi Rb-82, or An eluate Sr-85 level of 0.1 μCi /mCi Rb-82. 2.7 Radiation Dosimetry The estimated absorbed radiation doses for Rb-82, Sr-82, and Sr-85 from an intravenous injection rubidium Rb- 82 chloride are shown in Table 3.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Rubidium Rb 82 in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rubidium Rb 82 in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • safety and effectiveness not established in pediatric patients

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Rubidium Rb 82 in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rubidium Rb 82 in pediatric patients.

Contraindications

  • Condition1

Warnings

WARNING: UNINTENDED STRONTIUM-82 (SR-82) AND STRONTIUM-85 (SR-85) RADIATION EXPOSURE:
See full prescribing information for complete Boxed Warning.
UNINTENDED STRONTIUM-82 (SR-82) AND STRONTIUM-85 (SR-85) RADIATION EXPOSURE:
  • Unintended radiation exposure occurs when the levels of Sr-82 or Sr-85 in the rubidium Rb 82 chloride injection exceed specified limits [see Warnings and Precautions (5.1)]

Perform generator eluate tests:

Record each generator eluate volume, including waste and test volumes, and keep a record of the cumulative eluate volume [see Dosage and Administration (2.4)]. Determine Rb-82, Sr-82, Sr-85 in the generator eluate: ●Once a day, prior to any drug administrations, and ●At additional daily tests after detection of an Alert Limit. Alert Limits are: ○14 L for the generator’s cumulative eluate volume, or ○An eluate Sr-82 level of 0.002 μCi/ mCi Rb-82, or ○An eluate Sr-85 level of 0.02 Sr-85 μCi/ mCi Rb-82. ○Perform the additional daily tests at time points determined by the day’s elution volume; tests are performed every 750 mL [see Dosage and Administration (2.5)]. Stop use of a generator at an Expiration Limit of: ○17 L for the generator’s cumulative eluate volume, or ○42 days post generator calibration date, or ○An eluate Sr-82 level of 0.01 μCi /mCi Rb-82, or

○An eluate Sr-85 level of 0.1 μCi /mCi Rb-82
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Rubidium Rb 82 in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Rubidium Rb 82 in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Rubidium Rb 82 in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Rubidium Rb 82 during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Rubidium Rb 82 with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Rubidium Rb 82 with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Rubidium Rb 82 with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Rubidium Rb 82 with respect to specific gender populations.

Race

There is no FDA guidance on the use of Rubidium Rb 82 with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Rubidium Rb 82 in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Rubidium Rb 82 in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Rubidium Rb 82 in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Rubidium Rb 82 in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Rubidium Rb 82 in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Rubidium Rb 82 in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Rubidium Rb 82 in the drug label.

Pharmacology

There is limited information regarding Rubidium Rb 82 Pharmacology in the drug label.

Mechanism of Action

Structure

File:Rubidium Rb 8201.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Rubidium Rb 82 in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Rubidium Rb 82 in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Rubidium Rb 82 in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Rubidium Rb 82 in the drug label.

How Supplied

Storage

There is limited information regarding Rubidium Rb 82 Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Rubidium Rb 82 |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Rubidium Rb 82 |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Rubidium Rb 82 in the drug label.

Precautions with Alcohol

  • Alcohol-Rubidium Rb 82 interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Empty citation (help)
  2. "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Rubidium Rb 82
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Rubidium Rb 82
 |Label Name=Rubidium Rb 8211.png

}}

{{#subobject:

 |Label Page=Rubidium Rb 82
 |Label Name=Rubidium Rb 8211.png

}}